Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

GlioPATH: Comparison of central metabolic routes and signaling pathways in IDH mutant and wildtype gliomas (WHO °II-IV)

Group picture

Malignant gliomas belong to the most feared types of cancer, due to their dismal prognosis, as well as direct consequences on cognitive function and quality of life. The mutation of isocitrate dehydrogenase (IDHmut) is of high prognostic relevance in malignant glioma. The IDH status has been connected with altered tryptophan (Trp) metabolism but the mechanism is unknown. Trp is intertwined with central cancer metabolism (nicotinamide adenine dinucleotide, NAD) and signaling pathways (mammalian target of rapamycin, mTOR; aryl hydrocarbon receptor, AHR), but their dynamic interplay and specific impact on drug responses remains elusive. A systems medicine approach integrating these central metabolic and signaling routes with clinical outcomes is currently missing. GlioPATH is an interdisciplinary (biomedical, theoretical, clinical) and synergistic team effort. Iterative computational-experimental approaches will establish the IDH-Trp-NAD-AHR- mTOR network structure and dynamics by integrating several existing data layers (transcriptomics, proteomics, epigenetic, clinical) from TCGA database with metabolomic and kinetic biochemical analyses of glioma tissues (NCT tissue bank). GlioPATH will enable an improved understanding of gliomagenesis and provide the basis to identify possible combinatorial intervention strategies for individualized glioma therapy. GlioPATH will allow us to establish an innovative scientific network by fostering horizontal knowledge transfer within our network and with the systems medicine community.

to top
powered by webEdition CMS